Skip to main content Accessibility help
×
Hostname: page-component-77c89778f8-fv566 Total loading time: 0 Render date: 2024-07-17T14:02:44.597Z Has data issue: false hasContentIssue false

101 - Olanzapine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Zyprexa, Zyprexa Zydis, Zyprexa Relprevv, Zyprexa IntraMuscular, Symbyax (olanzapine/fluoxetine)

Generic?

• Ye

• Atypical antipsychotic

Commonly Prescribed for

(FDA approved in bold)

Schizophrenia for adolescents or adults

Monotherapy for bipolar I disorder, manic or mixed episode

Adjunct therapy to valproate or lithium for bipolar I disorder, manic or mixed episode

Bipolar I depression (Symbyax only)

Treatment-resistant depression (Symbyax only)

Acute agitation associated with schizophrenia and bipolar I mania (IntraMuscular only)

• Augmentation for refractory obsessivecompulsive disorder

• Migraine refractory to standard treatment

• Acute psychosis

• Delirium

• Antiemetic

How the Drug Works

• It is a thiobenzodiazepine derivative that binds strongly to 5-HT2A/2B/2C, 5-HT6, D1-5, H1,2, and α1,2 receptors, and moderately to 5-HT3 and M1-5 receptors. It exerts the action via D2 antagonism (for positive symptoms), 5-HT2A antagonism (negative symptoms), and 5-HT3 antagonism (antiemetic)

How Long Until It Works

• Migraine: hours. Often use to initiate sleep

• Schizophrenia/bipolar: may be effective in days, more commonly takes weeks or months to determine best dose and achieve best clinical effect. Usually 4–6 weeks

• Agitation/insomnia: may be effective Immediately

if It Works

• Continue to use at lowest required dose. Most patients with schizophrenia see a reduction in psychosis with neuroleptics

If It Doesn't Work

• Increase dose

• Psychosis related to Parkinson's disease (PD) or dementia with Lewy bodies (DLB): clozapine is more efficacious. For acute treatment only

• Insomnia: if no sedation occurs despite adequate dosing, change to another agent

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Patients with affective disorders, such as bipolar disorder, may respond to moodstabilizing AEDs, lithium, or benzodiazepines. For PD/DLB, treating dementia and psychosis with rivastigmine/donepezil and clozapine, respectively, may be efficacious

Tests

• Prior to starting treatment and periodically during treatment, monitor weight, blood pressure, lipids, and fasting glucose due to risk of metabolic syndrome

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 371 - 374
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Olanzapine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.102
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Olanzapine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.102
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Olanzapine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.102
Available formats
×